Network Modeling Predicts How DYRK1A Inhibition Promotes Cardiomyocyte Cycling after Ischemic/Reperfusion Injury

Technical Summary: Network Modeling Predicts How DYRK1A Inhibition Promotes Cardiomyocyte Cycling after Ischemic/Reperfusion Injury

Problem Statement
The adult mammalian heart possesses a severely limited capacity to regenerate myocardium following a myocardial infarction (MI). This regenerative failure is primarily attributed to the inability of cardiomyocytes (CMs) to re-enter the cell cycle and proliferate after injury. While Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) is established as a regulator of cell quiescence, the specific molecular mechanisms by which it governs the cell cycle in CMs remain poorly understood. Although previous research demonstrated that pharmacological inhibition of DYRK1A (e.g., using harmine) can induce cell cycle re-entry in the context of ischemia/reperfusion (I/R) injury, a comprehensive mechanistic model explaining how this inhibition drives proliferation is lacking.

Methodology
To address this gap, the authors employed a multi-faceted approach combining computational modeling with experimental validation:

1. Computational Network Modeling: A computational network model was developed to simulate DYRK1A-mediated regulation of the cell cycle. This model was designed to predict the specific mechanisms through which DYRK1A inhibition facilitates CM re-entry.
2. In Vitro Validation: The predictions derived from the network model were tested using selective DYRK1A inhibitors on neonatal rat cardiomyocytes (NRCMs) to observe cell cycle activity.
3. Transcriptomic Integration: The computational model was integrated with bulk RNA-sequencing (RNA-seq) data obtained from NRCMs treated with DYRK1A inhibitors. This integration aimed to identify key transcriptional drivers responsible for the observed changes in cell cycle gene expression.
4. In Vivo Functional Assessment: The study evaluated the therapeutic potential of DYRK1A inhibition in a living system by administering both pharmacological inhibitors and post-developmental inhibition strategies in models of I/R MI. Outcomes were measured via heart function metrics and the quantification of CM cycling.

Key Contributions and Results

• Mechanistic Prediction and Validation: The computational network model successfully predicted the mechanisms by which DYRK1A inhibition promotes CM re-entry. Experimental validation confirmed that selective inhibition of DYRK1A robustly induces cell cycle activity in NRCMs, aligning with the model's forecasts.
• Identification of E2F1: Through the integration of the network model with RNA-seq data, the study identified E2F1 as a critical transcriptional driver of cell cycle gene expression downstream of DYRK1A inhibition.
• Functional Recovery and Proliferation: The study demonstrated that both pharmacological inhibition and post-developmental inhibition of DYRK1A lead to enhanced heart function and a measurable increase in CM cycling following I/R MI.

Significance
The paper concludes that the functional recovery observed in the heart following the administration of small molecule inhibitors of DYRK1A is directly mediated by the induction of cycling cardiomyocytes. By elucidating the role of DYRK1A as a gatekeeper of quiescence and identifying E2F1 as a downstream effector, this work provides a mechanistic basis for targeting DYRK1A to promote myocardial regeneration after injury. The findings support the potential of DYRK1A inhibition as a therapeutic strategy to overcome the limited regenerative capacity of the adult mammalian heart.